…. Below we summarize the clinical trial data from GW’s Epidiolex in epilepsy and psychiatric indications, and Zynerba’s transdermal CBD gel ZYNOO2 in Fragile X syndrome. GW conducted a broad Phase III program for Epidiolex in epilepsy, cons...
COLLABORATIVE INSIGHTS February 25, 2019
IMAGES-008-HOUSE_OVERSIGHT_024903.txt
p.1
View source release ↗